| For: | Grillo F, Fassan M, Sarocchi F, Fiocca R, Mastracci L. HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice. World J Gastroenterol 2016; 22(26): 5879-5887 [PMID: 27468182 DOI: 10.3748/wjg.v22.i26.5879] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i26/5879.htm |
| Number | Citing Articles |
| 1 |
Chen Xu, Yalan Liu, Dongxian Jiang, Qian Li, Xiaowen Ge, Ying Zhang, Jie Huang, Jieakesu Su, Yuan Ji, Jun Hou, Shaohua Lu, Yingyong Hou, Tianshu Liu. Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type. Oncotarget 2017; 8(20) doi: 10.18632/oncotarget.16567
|
| 2 |
Markus Möhler, Salah-Eddin Al-Batran, Thorsten Oliver Götze. Therapie-Handbuch - Onkologie und Hämatologie. 2022; doi: 10.1016/B978-3-437-23824-6.00036-5
|
| 3 |
Paola Parente, Federica Grillo, Alessandro Vanoli, Luca Mastracci, Matteo Fassan. A charming molecular profile in the wrong tissue: the pathologist in the era of molecular diagnostics in the gastrointestinal tract. Expert Review of Molecular Diagnostics 2023; 23(12) doi: 10.1080/14737159.2023.2288267
|
| 4 |
Matteo Fassan, Stefano Brignola, Gianmaria Pennelli, Giulia Alberti, Valentina Angerilli, Alessandra Bressan, Antonio Pellino, Cristiano Lanza, Roberta Salmaso, Sara Lonardi, Salvatore Pucciarelli, Gaya Spolverato, Marco Scarpa, Stefano Realdon, Fabio Farinati, Claudio Luchini, Massimo Rugge, Fotios Loupakis. PD-L1 expression in gastroesophageal dysplastic lesions. Virchows Archiv 2020; 477(1) doi: 10.1007/s00428-019-02693-8
|
| 5 |
Konstantin Koro, Paul E. Swanson, Matthew M. Yeh. HER2 Testing in Gastric and Gastroesophageal Adenocarcinoma—Review and Update. AJSP: Reviews and Reports 2019; 24(4) doi: 10.1097/PCR.0000000000000322
|
| 6 |
Paolo Tarantino, Luca Mazzarella, Antonio Marra, Dario Trapani, Giuseppe Curigliano. The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. Cancer Treatment Reviews 2021; 94 doi: 10.1016/j.ctrv.2021.102169
|
| 7 |
Tomonori Tanei, Shigeto Seno, Yoshiaki Sota, Takaaki Hatano, Yuri Kitahara, Kaori Abe, Nanae Masunaga, Masami Tsukabe, Tetsuhiro Yoshinami, Tomohiro Miyake, Masafumi Shimoda, Hideo Matsuda, Kenzo Shimazu. High HER2 Intratumoral Heterogeneity Is a Predictive Factor for Poor Prognosis in Early-Stage and Locally Advanced HER2-Positive Breast Cancer. Cancers 2024; 16(5) doi: 10.3390/cancers16051062
|
| 8 |
Nina Eissler, Renske Altena, Ali Alhuseinalkhudhur, Olga Bragina, Joachim Feldwisch, Guido Wuerth, Annika Loftenius, Nikolai Brun, Rimma Axelsson, Vladimir Tolmachev, Jens Sörensen, Fredrik Y. Frejd. Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy. Biomedicines 2024; 12(5) doi: 10.3390/biomedicines12051088
|
| 9 |
Fedor Wadi Richani Meinhardt, Mijail I. Zambrano Iglesias, María P. Fernández Gómez, Jesús F. Saltaren Fonseca, Atif Hussein, Luis E. Raez. HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC). International Journal of Molecular Sciences 2026; 27(11) doi: 10.3390/ijms27114910
|
| 10 |
Nina Zhou, Chang Liu, Xiaoyi Guo, Yuping Xu, Jifang Gong, Changsong Qi, Xiaotian Zhang, Min Yang, Hua Zhu, Lin Shen, Zhi Yang. Impact of 68Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring. European Journal of Nuclear Medicine and Molecular Imaging 2021; 48(1) doi: 10.1007/s00259-020-04898-5
|
| 11 |
. 2024; doi: 10.70675/cbb59969z7ce8z4c29z9e5eza9f0122f6e43
|
| 12 |
Deborah Saraggi, Francesca Galuppini, Giuseppe N. Fanelli, Andrea Remo, Emanuele D.L. Urso, Ricardo Q. Bao, Deborah Bacchin, Vincenza Guzzardo, Claudio Luchini, Chiara Braconi, Fabio Farinati, Massimo Rugge, Matteo Fassan. MiR-21 up-regulation in ampullary adenocarcinoma and its pre-invasive lesions. Pathology - Research and Practice 2018; 214(6) doi: 10.1016/j.prp.2018.04.018
|
| 13 |
Andra M. Sterea, Emmanuel E. Egom, Yassine El Hiani. TRP channels in gastric cancer: New hopes and clinical perspectives. Cell Calcium 2019; 82 doi: 10.1016/j.ceca.2019.06.007
|
| 14 |
Markus Möhler, Salah-Eddin Al-Batran, Thorsten Oliver Götze. Therapie-Handbuch - Gastroenterologie und Hepatologie. 2021; doi: 10.1016/B978-3-437-23847-5.00016-8
|
| 15 |
Maluki Radford, Hassan Abushukair, Stijn Hentzen, Ludimila Cavalcante, Anwaar Saeed. Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era. Journal of Immunotherapy and Precision Oncology 2023; 6(3) doi: 10.36401/JIPO-22-36
|
| 16 |
A Beginner's Guide to Targeted Cancer Treatments and Cancer Immunotherapy. 2025; doi: 10.1002/9781119834090.ch3
|
| 17 |
Anna Grenda, Kamila Wojas-Krawczyk, Tomasz Skoczylas, Paweł Krawczyk, Jadwiga Sierocińska-Sawa, Grzegorz Wallner, Janusz Milanowski. HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery. BMC Gastroenterology 2020; 20(1) doi: 10.1186/s12876-020-01531-5
|
| 18 |
Pırıltı Özcan, Tuğçe Kübra Güneş, Ozgul Duzgun, Melike Özçelik. Challenges in Solid Tumors and Other Cancers: An Interdisciplinary Approach. Interdisciplinary Cancer Research 2024; 21 doi: 10.1007/16833_2024_220
|
| 19 |
Yesim Gurbuz, Nusret Erdogan. Risk Factors and Therapy of Esophagus Cancer. 2024; doi: 10.1007/978-3-031-47024-0_38
|
| 20 |
Anissa Moktefi, Damien Pouessel, Jing Liu, Nanor Sirab, Pascale Maille, Pascale Soyeux, Christiane Copie Bergman, Marie Luce Auriault, Dimitri Vordos, Alexandre de la Taille, Stéphane Culine, Yves Allory. Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility. Modern Pathology 2018; 31(8) doi: 10.1038/s41379-018-0023-9
|
| 21 |
Charalampos Theocharopoulos, Ioannis A. Ziogas, Benedetto Mungo, Helen Gogas, Dimitrios C. Ziogas, Elissaios Kontis. HER2-targeted therapies: Unraveling their role in biliary tract cancers. Critical Reviews in Oncology/Hematology 2025; 208 doi: 10.1016/j.critrevonc.2025.104655
|
| 22 |
Yalan Liu, Lingli Chen, Dongxian Jiang, Lijuan Luan, Jie Huang, Yingyong Hou, Chen Xu. HER2 promotes epithelial-mesenchymal transition through regulating osteopontin in gastric cancer. Pathology - Research and Practice 2021; 227 doi: 10.1016/j.prp.2021.153643
|
| 23 |
Elnaz Faghfuri, Mahdi Abdoli Shadbad, Amir Hossein Faghfouri, Narges Soozangar. Cellular Immunotherapy in Gastric Cancer: Adoptive Cell Therapy and Dendritic Cell-Based Vaccination. Immunotherapy 2022; 14(6) doi: 10.2217/imt-2021-0285
|
| 24 |
Francesca Salani, Silvia Catanese, Lorenzo Fornaro, Enrico Vasile, Clara Ugolini, Andrea Cacciato Insilla, Daniela Campani, Gabriella Fontanini, Gianluca Masi, Caterina Vivaldi. In Reply. The Oncologist 2021; 26(10) doi: 10.1002/onco.13886
|
| 25 |
Nelia Marina Rosanu, Lorenzo Gervaso, Renato Lobrano, Alessandro Vanoli, Chiara Alessandra Cella, Nicola Fusco, Nicola Fazio. Diagnostic and Therapeutic Challenges Related to HER2 Heterogeneity in Gastric Cancer: Bridging Molecular Pathology and Clinical Decision-Making. International Journal of Molecular Sciences 2026; 27(3) doi: 10.3390/ijms27031542
|
| 26 |
Matthew W. Rosenbaum, Raul S. Gonzalez. Immunohistochemistry as predictive and prognostic markers for gastrointestinal malignancies. Seminars in Diagnostic Pathology 2022; 39(1) doi: 10.1053/j.semdp.2021.10.003
|
| 27 |
Kohei Shitara, Elena Elimova, Tianshu Liu, Josep Tabernero, Keun-Wook Lee, Michael Schenker, Niall C. Tebbutt, Jaffer Ajani, Norhidayu Salimin, Geoffrey Ku, Jong Gwang Kim, Inmaculada Ales Diaz, Jingdong Zhang, Filippo Pietrantonio, Li-Yuan Bai, Samuel Le Sourd, Jun Zhao, Cinta Hierro, Andrew Kiberu, Filip Van Herpe, Yuanyuan Bao, Hanze Zhang, Lin Yang, Vincent Li, Elaina M. Gartner, Ye Chen, Jonathan Grim, Sun Young Rha, Lin Shen. Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer. New England Journal of Medicine 2026; 394(20) doi: 10.1056/NEJMoa2517729
|
| 28 |
Marek Kos, Krzysztof Bojarski, Milena Czosnek, Jan Śnieżyński, Bartosz Wilczyński, Paulina Mertowska, Ewelina Grywalska, Sebastian Mertowski. Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers. Cancers 2026; 18(16) doi: 10.3390/cancers18162675
|
| 29 |
Tao Huang, Hong Wei Liu, Jia Qi Chen, Shou Han Wang, Li Qun Hao, Miao Liu, Bin Wang. The long noncoding RNA PVT1 functions as a competing endogenous RNA by sponging miR-186 in gastric cancer. Biomedicine & Pharmacotherapy 2017; 88 doi: 10.1016/j.biopha.2017.01.049
|
| 30 |
Meng Yang, Wuhao Lin, Jiaqian Huang, Alessandro Mannucci, Huiyan Luo. Novel immunotherapeutic approaches in gastric cancer. Precision Clinical Medicine 2024; 7(4) doi: 10.1093/pcmedi/pbae020
|
| 31 |
Kyosuke Seguchi, Akihito Kawazoe, Izuma Nakayama, Kohei Shitara. An evaluation of pembrolizumab with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1). Expert Review of Anticancer Therapy 2026; 26(8) doi: 10.1080/14737140.2026.2628069
|
| 32 |
A. Ieni, G. Angelico, P. Zeppa, G. Tuccari. Letter to the Editor regarding the paper by Park et al., Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). European Journal of Cancer 2017; 75 doi: 10.1016/j.ejca.2017.01.015
|
| 33 |
Dione van Dijk, Lisa Vermij, Alicia León-Castillo, Melanie Powell, Jan Jobsen, Alexandra Leary, David Bowes, Linda Mileshkin, Catherine Genestie, Ina Jürgenliemk-Schulz, Cor de Kroon, Cathelijne Post, Stephanie de Boer, Linda Nooij, Judith Kroep, Carien Creutzberg, Vincent Smit, Nanda Horeweg, Tjalling Bosse, Anneke Westermann. Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2–Low. Journal of Clinical Oncology 2025; 43(4) doi: 10.1200/JCO.23.02768
|
| 34 |
Jessica Gasparello, Carlotta Ceccon, Valentina Angerilli, Tatiane Comunello, Marianna Sabbadin, Felipe D'Almeida Costa, Antonio Antico, Claudio Luchini, Paola Parente, Francesca Bergamo, Sara Lonardi, Matteo Fassan. Liquid biopsy in gastric cancer: A snapshot of the current state of the art. The Journal of Liquid Biopsy 2025; 7 doi: 10.1016/j.jlb.2025.100288
|
| 35 |
Qing Shen, Wanqian Zhang, Ying Chen. Case Report: Synchronous cutaneous and pineal metastases from gastric adenocarcinoma—inter-lesion biomarker heterogeneity and multi-line targeted therapy. Frontiers in Oncology 2026; 16 doi: 10.3389/fonc.2026.1924850
|
| 36 |
Hu Li, Xiao Zhang, Zhenyi Xu, Lingrui Li, Wenchao Liu, Zhenyu Dai, Zhongrun Zhao, Lili Xiao, Hongfeng Li, Chaohong Hu. Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors. Antibody Therapeutics 2021; 4(3) doi: 10.1093/abt/tbab017
|
| 37 |
Hongjian Zhao, Chunyan Huang, Mei Lin, Mingqing Zhou, Chunjin Huang. Dynamic detection of HER2 of circulating tumor cells in patients with gastric carcinoma and its clinical application. Molecular Medicine Reports 2022; 25(5) doi: 10.3892/mmr.2022.12703
|
| 38 |
Christiana Mo, Michelle Sterpi, Hyein Jeon, Fernand Bteich. Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies. Cancers 2024; 16(16) doi: 10.3390/cancers16162854
|
| 39 |
Tamara Zenz, Robert Jenke, René Thieme, Tim Kahl, Hannes Borchardt, Ines Gockel, Finn K. Hansen, Achim Aigner, Thomas R. H. Büch. The Histone Deacetylase Inhibitor Entinostat Mediates HER2 Downregulation in Gastric Cancer, Providing the Basis for Its Particular Efficacy in HER2-Amplified Tumors and in Combination Therapies. Cancer Research and Treatment 2025; 57(3) doi: 10.4143/crt.2024.546
|
| 40 |
Wenhao Ren, Qian Wang, Yiyi Guo, Haizhu Jin, Xiuli Ma, Yanli Zhu. Malignant effusions serve as a feasible source for therapy-related biomarker testing in advanced gastric cancer. Journal of Clinical Pathology 2026; 79(6) doi: 10.1136/jcp-2026-210622
|
| 41 |
Francesca Battaglin, Madiha Naseem, Alberto Puccini, Heinz-Josef Lenz. Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. Cancer Cell International 2018; 18(1) doi: 10.1186/s12935-018-0594-z
|
| 42 |
Keita Kai, Yukie Yoda, Atsushi Kawaguchi, Akimichi Minesaki, Hironori Iwasaki, Shinichi Aishima, Hirokazu Noshiro. Formalin fixation on HER-2 and PD-L1 expression in gastric cancer: A pilot analysis using the same surgical specimens with different fixation times. World Journal of Clinical Cases 2019; 7(4): 419-430 doi: 10.12998/wjcc.v7.i4.419
|
| 43 |
Matthew W Rosenbaum, Raul S Gonzalez. Targeted therapy for upper gastrointestinal tract cancer: current and future prospects. Histopathology 2021; 78(1) doi: 10.1111/his.14244
|
| 44 |
Takahiro Ishii, Kohei Shitara. Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer. Expert Review of Anticancer Therapy 2021; 21(11) doi: 10.1080/14737140.2021.1982698
|
| 45 |
Uqba Khan, Manish A. Shah. Emerging role of antibody–drug conjugates in gastrointestinal malignancies. Cancer 2026; 132(S1) doi: 10.1002/cncr.70419
|
| 46 |
Donaciano Flores-Robles, Antonio Celestino Montes, Jorge Antonio Perez Saldaña, Vanessa Del Razo-González, Gabriela Sanchez-Esgua, Martin Perez-Santos. Trispecific anti-CLDN-18.2/CD3/CD28 antibodies for gastric cancer treatment. Pharmaceutical Patent Analyst 2024; 13(4-6) doi: 10.1080/20468954.2025.2535943
|
| 47 |
Celine Hoyek, Binbin Zheng-Lin, Jeremy Jones, Tanios Bekaii-Saab. Tucatinib in the treatment of HER2-overexpressing gastrointestinal cancers: current insights and future prospects. Expert Opinion on Investigational Drugs 2025; 34(3) doi: 10.1080/13543784.2025.2472411
|
| 48 |
Antonella Cammarota, Rachel Woodford, Elizabeth C. Smyth. Targeting HER2 in Gastroesophageal Cancer: A New Appetite for an Old Plight. Drugs 2025; 85(3) doi: 10.1007/s40265-024-02132-2
|
| 49 |
Thi Yen Le, Lan Anh Thi Dinh, Van Thi Nguyen, Chu Van Nguyen, Thi Han Pham, Oanh Thi Bui, Thi Thu Huong Nguyen. Efficacy and Safety of mDCF as First-Line Therapy for HER2-Negative Advanced Gastric Cancer in Vietnam: A Real-World Retrospective Study. Cancer Control 2025; 32 doi: 10.1177/10732748251371771
|
| 50 |
Qian Li, Minzhi Lv, Lihua Lv, Nida Cao, Aiguang Zhao, Jiayan Chen, Xi Tang, Rongkui Luo, Shan Yu, Yan Zhou, Yuehong Cui, Wei Guo, Tianshu Liu. Identifying HER2 from serum‐derived exosomes in advanced gastric cancer as a promising biomarker for assessing tissue HER2 status and predicting the efficacy of trastuzumab‐based therapy. Cancer Medicine 2023; 12(4) doi: 10.1002/cam4.5269
|
| 51 |
Balázs Váradi, Károly Brezovcsik, Zoltán Garda, Enikő Madarasi, Horea Szedlacsek, Rodica-Aura Badea, Andrei-Mihai Vasilescu, Adina-Gabriela Puiu, Aura Elena Ionescu, Livia-Elena Sima, Cristian V. A. Munteanu, Simona Călăraş, Adrienn Vágner, Dezső Szikra, Ngô Minh Toàn, Tibor Nagy, Zoltán Szűcs, Stefan Szedlacsek, Gábor Nagy, Gyula Tircsó. Synthesis and characterization of a novel [52Mn]Mn-labelled affibody based radiotracer for HER2+ targeting. Inorganic Chemistry Frontiers 2023; 10(16) doi: 10.1039/D3QI00356F
|
| 52 |
Takaaki Iwado, Yoshiyasu Kono, Motoyuki Otsuka. HER2 reassessment triggered by comprehensive genomic profiling reveals a therapeutic opportunity in refractory gastric cancer: a case report. International Cancer Conference Journal 2025; 15(1) doi: 10.1007/s13691-025-00827-1
|
| 53 |
Valentina Angerilli, Filippo Ghelardi, Floriana Nappo, Federica Grillo, Paola Parente, Sara Lonardi, Claudio Luchini, Filippo Pietrantonio, Clara Ugolini, Alessandro Vanoli, Matteo Fassan. Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion. Pathology - Research and Practice 2024; 254 doi: 10.1016/j.prp.2024.155145
|
| 54 |
Harshabad Singh, Kristen E. Lowder, Kevin Kapner, Ronan J. Kelly, Hui Zheng, Nadine Jackson McCleary, Thomas A. Abrams, Jennifer A. Chan, Eileen M. Regan, Samuel J. Klempner, Alison M. Hannigan, Joshua Remland, Lauren K. Brais, Elizabeth Andrews, Matthew Yurgelun, James M. Cleary, Douglas A. Rubinson, Lauren L. Ritterhouse, Garrett Maron, Andrew J. Aguirre, Jeffrey A. Meyerhardt, Emma Gardecki, Jochen K. Lennerz, Brian M. Wolpin, Peter C. Enzinger. Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma. Nature Communications 2024; 15(1) doi: 10.1038/s41467-024-51271-3
|
| 55 |
Antonio Ieni, Roberta Cardia, Cristina Pizzimenti, Pio Zeppa, Giovanni Tuccari. HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies. Journal of Personalized Medicine 2020; 10(1) doi: 10.3390/jpm10010010
|
| 56 |
Darren Locke, Clifford C. Hoyt. Companion diagnostic requirements for spatial biology using multiplex immunofluorescence and multispectral imaging. Frontiers in Molecular Biosciences 2023; 10 doi: 10.3389/fmolb.2023.1051491
|
| 57 |
Gianluca Businello, Francesca Galuppini, Matteo Fassan. The impact of recent next generation sequencing and the need for a new classification in gastric cancer. Best Practice & Research Clinical Gastroenterology 2021; doi: 10.1016/j.bpg.2021.101730
|
| 58 |
Ming-Huang Chen, Sheng-Nan Lu, Chien-Hung Chen, Peng-Chan Lin, Jeng-Kai Jiang, Yulia D’yachkova, Mariusz Lukanowski, Rebecca Cheng, Li-Tzong Chen. How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?. Cancers 2021; 13(14) doi: 10.3390/cancers13143536
|
| 59 |
Seyed Morteza Pourfaraji, Alireza Abdollahi, Fatemeh Ojaghi Shirmard, Reza Ghalehtaki, Samaneh Salarvand. The Utility of HER2 Overexpression in Prognosis of Gastric Cancer: A Systematic Review and Meta‐Analysis Study. Cancer Reports 2026; 9(6) doi: 10.1002/cnr2.70612
|
| 60 |
Saori Mishima, Kohei Shitara. Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer. Expert Opinion on Biological Therapy 2021; 21(7) doi: 10.1080/14712598.2021.1912007
|
| 61 |
Shinnosuke Nagano, Yukinori Kurokawa, Takaomi Hagi, Yuichi Motoyama, Takuro Saito, Tsuyoshi Takahashi, Kota Momose, Kotaro Yamashita, Koji Tanaka, Tomoki Makino, Kiyokazu Nakajima, Eiichi Morii, Hidetoshi Eguchi, Yuichiro Doki. Intratumoral heterogeneity and chemotherapy-induced alteration of CLDN18.2 expression in resectable gastric cancer. International Journal of Clinical Oncology 2026; 31(4) doi: 10.1007/s10147-026-02972-w
|
| 62 |
Nicole M. Myer, Kohei Shitara, Hyun C. Chung, Florian Lordick, Ronan J. Kelly, Zsolt Szabo, Z. Alexander Cao, Stephen Leong, David H. Ilson, Wilko Weichert. Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer. Journal of Cancer Research and Clinical Oncology 2022; 148(8) doi: 10.1007/s00432-021-03902-1
|
| 63 |
Chen Xu, Yalan Liu, Xiaowen Ge, Dongxian Jiang, Ying Zhang, Yuan Ji, Jun Hou, Jie Huang, Jieakesu Su, Haiying Zeng, Jing Qin, Yingyong Hou. Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer. Diagnostic Pathology 2017; 12(1) doi: 10.1186/s13000-017-0616-5
|
| 64 |
Valentina Angerilli, Paola Parente, Michela Campora, Clara Ugolini, Serena Battista, Paola Cassoni, Alessandro Gambella, Francesco Cavallin, Giuseppe De Lisi, Alessandro Vanoli, Federica Grillo, Luca Mastracci, Matteo Fassan. HER2-low in gastro-oesophageal adenocarcinoma: a real-world pathological perspective. Journal of Clinical Pathology 2023; 76(12) doi: 10.1136/jcp-2023-208767
|
| 65 |
Ewald Wöll. Milestones in gastric cancer. memo - Magazine of European Medical Oncology 2017; 10(1) doi: 10.1007/s12254-017-0311-y
|
| 66 |
Giuseppe Nicolò Fanelli, Pierluigi Gasparini, Irene Coati, Ri Cui, Hubert Pakula, Basudev Chowdhury, Nicola Valeri, Fotios Loupakis, Juozas Kupcinskas, Rocco Cappellesso, Matteo Fassan. LONG-NONCODING RNAs in gastroesophageal cancers. Non-coding RNA Research 2018; 3(4) doi: 10.1016/j.ncrna.2018.10.001
|
| 67 |
Antonio Pellino, Stefano Brignola, Erika Riello, Monia Niero, Sabina Murgioni, Maria Guido, Floriana Nappo, Gianluca Businello, Marta Sbaraglia, Francesca Bergamo, Gaya Spolverato, Salvatore Pucciarelli, Stefano Merigliano, Pierluigi Pilati, Francesco Cavallin, Stefano Realdon, Fabio Farinati, Angelo Paolo Dei Tos, Vittorina Zagonel, Sara Lonardi, Fotios Loupakis, Matteo Fassan. Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. Journal of Personalized Medicine 2021; 11(11) doi: 10.3390/jpm11111095
|
| 68 |
Federica Grillo, Luca Mastracci, Luca Saragoni, Alessandro Vanoli, Francesco Limarzi, Irene Gullo, Jacopo Ferro, Michele Paudice, Paola Parente, Matteo Fassan. Neoplastic and pre-neoplastic lesions of the oesophagus and gastro-oesophageal junction. Pathologica 2020; 112(3) doi: 10.32074/1591-951X-164
|
| 69 |
Markus Möhler, Thorsten Oliver Götze. Therapie-Handbuch - Onkologie und Hämatologie. 2024; doi: 10.1016/B978-3-437-21011-2.00037-5
|
| 70 |
Tao Yang, Rui Xu, Junhao You, Fang Li, Bing Yan, Jia-nan Cheng. Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer. BMC Cancer 2022; 22(1) doi: 10.1186/s12885-022-10262-7
|
| 71 |
Natalia Gorbokon, Katharina Teljuk, Viktor Reiswich, Maximilian Lennartz, Sarah Minner, Ronald Simon, Guido Sauter, Waldemar Wilczak, Till Sebastian Clauditz, Nina Schraps, Thilo Hackert, Faik G. Uzunoglu, Martina Kluth, Lukas Bubendorf, Matthias Matter, Florian Viehweger, Morton Freytag, Frank Jacobsen, Katharina Möller, Stefan Steurer. Deficiency of MTAP Is Frequent and Mostly Homogeneous in Pancreatic Ductal Adenocarcinomas. Cancers 2025; 17(7) doi: 10.3390/cancers17071205
|
| 72 |
Markus Möhler, Thorsten Oliver Götze. Therapie-Handbuch - Gastroenterologie und Hepatologie. 2024; doi: 10.1016/B978-3-437-21005-1.00017-2
|
| 73 |
Ali Abdulnabi Suwaidan, David K. Lau, Ian Chau. HER2 targeted therapy in colorectal cancer: New horizons. Cancer Treatment Reviews 2022; 105 doi: 10.1016/j.ctrv.2022.102363
|
| 74 |
N. E. Ogurchenok, M. Yu. Agapov, G. A. Raskin. Problematic aspects of assessing predictive markers for gastric cancer based on endoscopic biopsy samples. Review. Clinical Case in Oncology 2025; 2(3) doi: 10.62546/3034-1477-2024-2-3-7-17
|
| 75 |
Manish A Shah, David Cunningham, Jean-Philippe Metges, Eric Van Cutsem, Zev Wainberg, Emon Elboudwarej, Kai-Wen Lin, Scott Turner, Marianna Zavodovskaya, David Inzunza, Jinfeng Liu, Scott D Patterson, Jingzhu Zhou, Jing He, Dung Thai, Pankaj Bhargava, Carrie Baker Brachmann, Daniel V T Cantenacci. Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival. Journal for ImmunoTherapy of Cancer 2021; 9(12) doi: 10.1136/jitc-2021-003580
|
| 76 |
Marco Palma. Advancing Breast Cancer Treatment: The Role of Immunotherapy and Cancer Vaccines in Overcoming Therapeutic Challenges. Vaccines 2025; 13(4) doi: 10.3390/vaccines13040344
|
| 77 |
Timil H. Patel, Michael Cecchini. Targeted Therapies in Advanced Gastric Cancer. Current Treatment Options in Oncology 2020; 21(9) doi: 10.1007/s11864-020-00774-4
|
| 78 |
Hisateru Yasui, Atsushi Takeno, Hiroki Hara, Hiroshi Imamura, Hiroki Akamatsu, Kazumasa Fujitani, Minoru Nakane, Chihiro Nakayama Kondoh, Seigo Yukisawa, Junichiro Nasu, Yoshinori Miyata, Akitaka Makiyama, Hiroyasu Ishida, Norimasa Yoshida, Eiji Matsumura, Masato Ishigami, Masahiro Sugihara, Atsushi Ochiai, Toshihiko Doi. Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer populations: DS-Screen Study. International Journal of Colorectal Disease 2022; 37(6) doi: 10.1007/s00384-022-04162-2
|
| 79 |
Sherry Shen, Weining Ma, David Brown, Arnaud Da Cruz Paula, Qin Zhou, Alexia Iaosonos, Basile Tessier-Cloutier, Dara S. Ross, Tiffany Troso-Sandoval, Jorge S. Reis-Filho, Nadeem Abu-Rustum, Yanming Zhang, Lora H. Ellenson, Britta Weigelt, Vicky Makker, M. Herman Chui. HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer. Modern Pathology 2023; 36(11) doi: 10.1016/j.modpat.2023.100299
|
| 80 |
Yi Rao, Zachary Samuels, Lukas M. Carter, Sebastien Monette, Sandeep Surendra Panikar, Patricia M. R. Pereira, Jason S. Lewis. Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers. Proceedings of the National Academy of Sciences 2023; 120(14) doi: 10.1073/pnas.2220413120
|
| 81 |
Shigehiro Koganemaru, Kohei Shitara. Antibody–drug conjugates to treat gastric cancer. Expert Opinion on Biological Therapy 2021; 21(7) doi: 10.1080/14712598.2020.1802423
|
| 82 |
Daisuke Kotani, Kohei Shitara. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Therapeutic Advances in Medical Oncology 2021; 13 doi: 10.1177/1758835920986518
|
| 83 |
Mary Kay Washington, Richard M. Goldberg, George J. Chang, Paul Limburg, Alfred K. Lam, Manuel Salto‐Tellez, Mark J. Arends, Iris D. Nagtegaal, David S. Klimstra, Massimo Rugge, Peter Schirmacher, Alexander J. Lazar, Robert D. Odze, Fatima Carneiro, Masashi Fukayama, Ian A. Cree. Diagnosis of digestive system tumours. International Journal of Cancer 2021; 148(5) doi: 10.1002/ijc.33210
|
| 84 |
Valentina Angerilli, Matilde Callegarin, Ilaria Govoni, Giuseppe De Lisi, Michele Paudice, Paola Fugazzola, Alessandro Vanoli, Paola Parente, Francesca Bergamo, Claudio Luchini, Angelo Paolo Dei Tos, Federica Grillo, Sara Lonardi, Luca Mastracci, Gaya Spolverato, Matteo Fassan. Heterogeneity of predictive biomarker expression in gastric and esophago-gastric junction carcinoma with peritoneal dissemination. Gastric Cancer 2025; 28(4) doi: 10.1007/s10120-025-01609-7
|
| 85 |
A. Ieni, G. Angelico, G. Giuffrè, G. Tuccari. Discordance Rate of HER2 Status in Primary Gastric Cancer and Synchronous Lymph Node Metastases: Its Impact on Therapeutic Decision and Clinical Management. Pathology & Oncology Research 2018; 24(3) doi: 10.1007/s12253-017-0276-5
|
| 86 |
Kexin Lan, Yongshun Liu, Ruobing Li, Zhaonan Sun, Wenpeng Huang. Molecular imaging in gastric cancer: state-of-the-art techniques and emerging opportunities. Journal of Translational Medicine 2026; 24(1) doi: 10.1186/s12967-026-08011-6
|
| 87 |
|
| 88 |
Zhen-Hua Liu, Bo-Wen Zhu, Min Shi, Yu-Rong Qu, Xun-Jun He, Hong-Ling Yuan, Jie Ma, Wei Li, Dan-Dan Zhao, Zheng-Chuang Liu, Bao-Ming Wang, Chun-Yang Wang, Hou-Quan Tao, Tong-Hui Ma. Profiling of gene fusion involving targetable genes in Chinese gastric cancer. World Journal of Gastrointestinal Oncology 2022; 14(8): 1528-1539 doi: 10.4251/wjgo.v14.i8.1528
|
| 89 |
Haixing Wang, Beifang Li, Zhentao Liu, Jifang Gong, Lin Shao, Jun Ren, Yunyun Niu, Shiping Bo, Zhongwu Li, Yumei Lai, Sijia Lu, Jing Gao, Lin Shen. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. European Journal of Cancer 2018; 88 doi: 10.1016/j.ejca.2017.10.032
|
| 90 |
Li-Fei Sun, Kun Yang, Yi-Gao Wang, Yu-Xin Liu, Pei-Xian Hou, Zheng-Hao Lu, Xiao-Long Chen, Wei-Han Zhang, Zong-Guang Zhou, Xian-Ming Mo, Jian-Kun Hu. The Role of HER2 in Self-Renewal, Invasion, and Tumorigenicity of Gastric Cancer Stem Cells. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.01608
|
| 91 |
Duminda Subasinghe, Sivasuriya Sivaganesh, Ananthi Samarsekera, Mariyan Priyanthi Kumarasinghe, Dharmabandhu Nandadeva Samarasekera, Menaka Dilani Samarwickrema Lokuhetty. Human Epidermal Growth Factor Receptor-2 in Sri Lankan Gastric Carcinoma Patients with Clinicopathological Association and Survival. Digestive Diseases and Sciences 2017; 62(9) doi: 10.1007/s10620-017-4647-2
|
| 92 |
Emma L. Brown, Shayla Shmuel, Komal Mandleywala, Sandeep Surendra Panikar, Na-Keysha Berry, Yi Rao, Abbey Zidel, Jason S. Lewis, Patrícia M.R. Pereira. Immuno-PET Detects Antibody–Drug Potency on Coadministration with Statins. Journal of Nuclear Medicine 2023; 64(10) doi: 10.2967/jnumed.122.265172
|
| 93 |
Kohei Shitara, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun-Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee, Kaku Saito, Yoshinori Kawaguchi, Takahiro Kamio, Akihito Kojima, Masahiro Sugihara, Kensei Yamaguchi. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. New England Journal of Medicine 2020; 382(25) doi: 10.1056/NEJMoa2004413
|
| 94 |
Chen Xu, Miaomiao Sun, Mei Jin, Zengshan Li, Rong Qin, Guoping Ren, Wenyong Sun, Lirong Chen, Lijuan Luan, Yalan Liu, Dongxian Jiang, Lingli Chen, Rongkui Luo, Yingyong Hou. Dual block HER2 assessment increased HER2 immunohistochemistry positive rate in resected specimens of gastric cancer: a prospective multicenter clinical trial from China. Diagnostic Pathology 2022; 17(1) doi: 10.1186/s13000-022-01230-7
|
| 95 |
Yingying Xu, Yakun Wang, Jifang Gong, Xiaotian Zhang, Zhi Peng, Xinan Sheng, Chenyu Mao, Qingxia Fan, Yuxian Bai, Yi Ba, Da Jiang, Fen Yang, Changsong Qi, Jian Li, Xicheng Wang, Jun Zhou, Ming Lu, Yanshuo Cao, Jiajia Yuan, Dan Liu, Zhenghang Wang, Jianmin Fang, Lin Shen. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer 2021; 24(4) doi: 10.1007/s10120-021-01168-7
|
| 96 |
Ross E Staudt, Robert D Carlson, Adam E Snook. Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy. Cancer Biology & Therapy 2022; 23(1) doi: 10.1080/15384047.2022.2033057
|
| 97 |
Jianjun Xi, Mingzheng Xu, Zongchang Song, Hongqiang Li, Shumin Xu, Chunmei Wang, Haihan Song, Jianwen Bai. Stimulatory role of interleukin 10 in CD8+T cells through STATs in gastric cancer. Tumor Biology 2017; 39(5) doi: 10.1177/1010428317706209
|
| 98 |
Seunghyun Kang, Donghyeok Seol, Jieun Lee, Chanmi Bang, Mira Yoo, Soyeon Kim, Sepil An, Hyeongjin Cho, Duyeong Hwang, So Hyun Kang, Young Suk Park, Sang-Hoon Ahn, Hyung-Ho Kim, Eunhee Yi, Sanghyun Kim, Yun-Suhk Suh, Hoon Kim. Extrachromosomal DNA amplifications exhibit distinct molecular characteristics and prognostic implications in gastric cancer. Cancer Letters 2026; 639 doi: 10.1016/j.canlet.2025.218214
|
| 99 |
Matteo Fassan, Federica Grillo, Paola Parente, Luca Mastracci, Alessandro Vanoli, Edoardo V. Savarino, Cristiano Spada, Fabio Farinati, Cesare Hassan, Renato Cannizzaro. The current success of precision oncology relies on precision diagnostics: how quality and quantity of endoscopic biopsies impact cancer patient outcome. Digestive and Liver Disease 2025; 57(9) doi: 10.1016/j.dld.2025.05.026
|
| 100 |
Guoying Jiang, Guobing Wang, Jun Tao, Wenqi Feng. Targeted nanocarriers in gastric cancer: a critical review of HER2, CLDN18.2 and EGFR-directed translational evidence. Beni-Suef University Journal of Basic and Applied Sciences 2026; 15(1) doi: 10.1186/s43088-026-00822-2
|
| 101 |
Valentina Angerilli, Juan José Andrade Rojas, Matteo Fassan. Principles of Immunotherapy Breast and Gastrointestinal Cancers. 2025; doi: 10.1016/B978-0-443-13376-3.00012-5
|
| 102 |
Hongpeng Lu, Zhihui Xu, Lihong Shao, Peifei Li, Yonghong Xia. High infiltration of immune cells with lower immune activity mediated the heterogeneity of gastric adenocarcinoma and promoted metastasis. Heliyon 2024; 10(17) doi: 10.1016/j.heliyon.2024.e37092
|
| 103 |
Jan-Mou Lee, Chia-Chun Tu, Chih-Hao Fang, Shian-Ren Lin, Shiu-Lan Wang, Wan-Yu Lai, Po-Wei Tseng, Wan-En Liao, Li-Yun Huang, Yee Chao, Ming-Huang Chen. Detecting HER2-positive circulating tumor cells in gastric cancer using a flow cytometry-based approach. Frontiers in Medicine 2025; 12 doi: 10.3389/fmed.2025.1672955
|
| 104 |
Hongsik Kim, Seung-Myoung Son, Chang Gok Woo, Ok-Jun Lee, Dae Hoon Kim, Hyo Yung Yun, Jieun Yun, Hee Kyung Kim, Yaewon Yang, Hye Sook Han. Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions. BMC Cancer 2019; 19(1) doi: 10.1186/s12885-019-6035-0
|
| 105 |
Federica Grillo, Alessandro Gambella, Silvia Bozzano, Michele Paudice, Nataniele Piol, Manuele Furnari, Stefania Sciallero, Alessandro Pastorino, Anna Maria Pessino, Paola Parente, Alessandro Vanoli, Matteo Fassan, Luca Mastracci. Number/quality of endoscopic biopsy samples in gastrointestinal cancers for biomarker testing: All that glitters is not gold. Digestive and Liver Disease 2026; 58(2) doi: 10.1016/j.dld.2025.12.005
|
| 106 |
Matteo Fassan, Aldo Scarpa, Andrea Remo, Giovanna De Maglio, Giancarlo Troncone, Antonio Marchetti, Claudio Doglioni, Giuseppe Ingravallo, Giuseppe Perrone, Paola Parente, Claudio Luchini, Luca Mastracci. Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice. Pathologica 2020; 112(3) doi: 10.32074/1591-951X-158
|
| 107 |
Irene Coati, Gábor Lotz, Giuseppe Nicolò Fanelli, Stefano Brignola, Cristiano Lanza, Rocco Cappellesso, Antonio Pellino, Salvatore Pucciarelli, Gaya Spolverato, Vincenza Guzzardo, Giada Munari, Giovanni Zaninotto, Marco Scarpa, Luca Mastracci, Fabio Farinati, Stefano Realdon, Pierluigi Pilati, Sara Lonardi, Nicola Valeri, Massimo Rugge, Andras Kiss, Fotios Loupakis, Matteo Fassan. Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. British Journal of Cancer 2019; 121(3) doi: 10.1038/s41416-019-0508-4
|
| 108 |
Raul S. Gonzalez, Anwar Raza, Robert Propst, Oyedele Adeyi, Justin Bateman, Sabrina C. Sopha, Janet Shaw, Aaron Auerbach. Recent Advances in Digestive Tract Tumors: Updates From the 5th Edition of the World Health Organization “Blue Book”. Archives of Pathology & Laboratory Medicine 2021; 145(5) doi: 10.5858/arpa.2020-0047-RA
|
| 109 |
Ju Yang, Zhan Shi, Xin Zhang, Qin Liu, Xiaobin Cui, Lin Li, Baorui Liu, Jia Wei. Real‐world clinical outcomes of the combination of anti‐PD‐1 antibody, trastuzumab, and chemotherapy for HER2‐positive gastric/gastroesophageal junction cancer. Cancer Medicine 2023; 12(8) doi: 10.1002/cam4.5722
|
| 110 |
François Fasquelle, Hugo Teixeira Farinha, Christine Sempoux, Sandrine Worreth, Nathalie Piazzon, David Fuks, Markus Schäfer, Styliani Mantziari. The tumor microenvironment in esophageal cancer and its association with clinical features and neoadjuvant treatment response. Scientific Reports 2026; 16(1) doi: 10.1038/s41598-026-36537-8
|
| 111 |
Antonio Ieni, Roberta Cardia, Maria Lentini, Giovanni Tuccari. Intratumoral HER2 heterogeneity in early gastric carcinomas: potential bias in therapeutic management. Virchows Archiv 2019; 474(3) doi: 10.1007/s00428-018-2502-2
|
| 112 |
. 2021; doi: 10.70675/68ea9779zddf2z4d17z9e21z2100d9fbb840
|
| 113 |
Ilya Tsimafeyeu, Grigory Raskin. Challenges of FGFR2 Testing in Gastric Cancer. Oncology Reviews 2023; 17 doi: 10.3389/or.2023.11790
|
| 114 |
Sören Weidemann, Natalia Gorbokon, Maximilian Lennartz, Claudia Hube-Magg, Christoph Fraune, Christian Bernreuther, Till S. Clauditz, Frank Jacobsen, Kristina Jansen, Barbara Schmalfeldt, Linn Wölber, Peter Paluchowski, Enikö Berkes, Uwe Heilenkötter, Guido Sauter, Ria Uhlig, Waldemar Wilczak, Stefan Steurer, Ronald Simon, Till Krech, Andreas Marx, Eike Burandt, Patrick Lebok. High Homogeneity of Mesothelin Expression in Primary and Metastatic Ovarian Cancer. Applied Immunohistochemistry & Molecular Morphology 2023; 31(2) doi: 10.1097/PAI.0000000000001097
|
| 115 |
Adrian Constantin, Roxana Constantin, Florin Achim, Bogdan Socea, Dragos Predescu. Pregnancy and Gastric Cancer: A Narrative Review. Diagnostics 2023; 13(11) doi: 10.3390/diagnostics13111909
|
| 116 |
Abdolreza Esmaeilzadeh, Davood Jafari, Reza Elahi, Mahsa Bazargan, Maryam Zare Rafie, Amir Hossein Mansourabadi. Challenges in Solid Tumors and Other Cancers: An Interdisciplinary Approach. Interdisciplinary Cancer Research 2023; 21 doi: 10.1007/16833_2023_156
|
| 117 |
Michael Herman Chui, David N Brown, Jorge S Reis‐Filho, Lora Hedrick Ellenson, Britta Weigelt. ERBB2 amplification is a late event in the pathogenesis of high‐grade endometrial carcinomas with heterogeneous HER2 expression. The Journal of Pathology 2026; 268(3) doi: 10.1002/path.70014
|
| 118 |
Dominika Bębnowska, Ewelina Grywalska, Paulina Niedźwiedzka-Rystwej, Barbara Sosnowska-Pasiarska, Jolanta Smok-Kalwat, Marcin Pasiarski, Stanisław Góźdź, Jacek Roliński, Wojciech Polkowski. CAR-T Cell Therapy—An Overview of Targets in Gastric Cancer. Journal of Clinical Medicine 2020; 9(6) doi: 10.3390/jcm9061894
|
| 119 |
Duminda Subasinghe, Nathan Acott, Pasyodun Koralage Buddhika Mahesh, Sivasuriya Sivaganesh, Sithum Munasinghe, Mariyan Priyanthi Kumarasinghe, Dharmabandu Nandaveva Samarasekera, Menaka Dilani Samarawickrema Lokuhetty. Human epidermal growth factor receptor-2 gene expression positivity determined by silver in situ hybridization/immunohistochemistry methods and associated factors in a cohort of Sri Lankan patients with gastric adenocarcinoma: a prospective study. Journal of International Medical Research 2023; 51(2) doi: 10.1177/03000605231154403
|
| 120 |
He Zhang, Yi Wang, Yanfeng Wang, Daoyuan Wu, Enguang Lin, Qingxin Xia. Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer. Pathology - Research and Practice 2020; 216(11) doi: 10.1016/j.prp.2020.153229
|
| 121 |
Mariia Ivanova, Elham Sajjadi, Lorenzo Zattoni, Nicola Fusco. Hereditary Gastric and Breast Cancer Syndrome. 2023; doi: 10.1007/978-3-031-21317-5_10
|
| 122 |
Isabella Michelon, Anwaar Saeed. Young-Onset Gastric Cancer: Clinical and Genetic Perspectives. Journal of Gastric Cancer 2026; 26(1) doi: 10.5230/jgc.2026.26.e9
|
| 123 |
Irene Gullo, Federica Grillo, Luca Mastracci, Alessandro Vanoli, Fatima Carneiro, Luca Saragoni, Francesco Limarzi, Jacopo Ferro, Paola Parente, Matteo Fassan. Precancerous lesions of the stomach, gastric cancer and hereditary gastric cancer syndromes. Pathologica 2020; 112(3) doi: 10.32074/1591-951X-166
|
| 124 |
Javier I Quezada‐Marín, Alfred K Lam, Atsushi Ochiai, Robert D Odze, Kay M Washington, Masashi Fukayama, Massimo Rugge, David S Klimstra, Iris D Nagtegaal, Puay‐Hoon Tan, Mark J Arends, John R Goldblum, Ian A Cree, Manuel Salto‐Tellez. Gastrointestinal tissue‐based molecular biomarkers: a practical categorisation based on the 2019 World Health Organization classification of epithelial digestive tumours. Histopathology 2020; 77(3) doi: 10.1111/his.14120
|
| 125 |
延璐 赵. Research Status of Circulating Tumor Cells in Gastric Cancer and Their Clinical Significance. Journal of Clinical Personalized Medicine 2024; 3(02) doi: 10.12677/jcpm.2024.32057
|
| 126 |
Daiki Ohsaki, Kazuki Kanayama. Downregulation of kinetochore‑associated 1 gene increases lagging chromosomes and contributes to chromosomal instability in gastric cancer cells. Medicine International 2025; 5(5) doi: 10.3892/mi.2025.258
|
| 127 |
Nathalie Baudoux, Francine Aubin. The Role of Biomarkers in Upper Gastrointestinal Cancers. Canadian Oncology Today 2025; doi: 10.58931/cot.2025.2133
|
| 128 |
G.A. Raskin, M.S. Mukhina, E.D. Kravtsova, I.V. Tsimafeyeu, S.A. Tyulandin, N.P. Belyak, M.A. Kleshchev, R.V. Orlova. Study of FGFR2 status in gastric cancer by immunohistochemistry and fluorescent in situ hybridization. Russian Journal of Archive of Pathology 2023; 85(3) doi: 10.17116/patol20238503140
|
| 129 |
Rui Liu, Xia Wang, Zhi Ji, Ting Deng, Hong-Li Li, Yan-Hui Zhang, Yu-Chong Yang, Shao-Hua Ge, Le Zhang, Ming Bai, Tao Ning, Yi Ba. Toripalimab combined with targeted therapy and chemotherapy achieves pathologic complete response in gastric carcinoma: A case report. World Journal of Clinical Cases 2022; 10(18): 6184-6191 doi: 10.12998/wjcc.v10.i18.6184
|
| 130 |
Anderley Gordon, Edwina Johnston, David K Lau, Naureen Starling. Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments. OncoTargets and Therapy 2022; doi: 10.2147/OTT.S282718
|
| 131 |
Pegah Mousavi, Ali Ahmadi, Shakila Behzadifar, Javad Mohammadnejad, Seyed Mohammad Hosseini. Gastric Cancer - Progress and Challenges in the Era of Precision Medicine. 2024; doi: 10.5772/intechopen.1005783
|
| 132 |
梦薇 涂. Research Progress and Clinical Translational Prospects of Molecular Biomarkers in the Early Diagnosis of Gastric Cancer. Advances in Clinical Medicine 2025; 15(12) doi: 10.12677/acm.2025.15123440
|
| 133 |
Hye Seung Lee. Spatial and Temporal Tumor Heterogeneity in Gastric Cancer: Discordance of Predictive Biomarkers. Journal of Gastric Cancer 2025; 25(1) doi: 10.5230/jgc.2025.25.e3
|
| 134 |
Jan Albin, Luca Fahrig, Janna Siemanowski, Jan Rehkaemper, Florian Gebauer, Thomas Zander, Reinhard Buettner, Christiane Josephine Bruns, Wolfgang Schroeder, Hakan Alakus, Lena Hieggelke, Alexander Quaas. FGFR2-amplified tumor clones are markedly heterogeneously distributed in carcinomas of the upper gastrointestinal tract. Journal of Cancer Research and Clinical Oncology 2023; 149(8) doi: 10.1007/s00432-022-04460-w
|
| 135 |
Ximena Baez-Navarro, Floris H. Groenendijk, Lindsey Oudijk, Jan von der Thüsen, Nicola Fusco, Giuseppe Curigliano, Carolien H.M. van Deurzen. HER2-low across solid tumours: different incidences and definitions. Pathology 2025; 57(4) doi: 10.1016/j.pathol.2025.02.003
|